CEO Paul McKenzie announced a reaffirmation of guidance for fiscal 2025, targeting NPATA growth of 10% to 13%. He highlighted strong results from CSL Behring and growth in CSL Vifor, while ...

The Behring unit, which makes up around 70% of CSL's revenue, recorded a 15% jump in immunoglobulin sales to $3.17 billion, ...

Finally, CSL Vifor sales were up 6% to US$1.08 billion for the six months. This was driven by continued volume growth for iron products in Europe, despite generic competition, and strong Tavneos ...

Travere Therapeutics and partner CSL Vifor could be weeks away from EU approval of sparsentan for IgA nephropathy, after getting a positive opinion on the drug from the EMA’s human medicines ...

Carlisle Companies Incorporated operates as a manufacturer and supplier of building envelope products and solutions in the United States, Europe, North America, Asia and the Middle East, Africa ...

CSL shares tumbled 4.95% on the day of its half-year results after revenue, net profits and dividends missed market ...

The joint company will be 55% owned by Vifor Pharma and 45% by Fresenius Kabi. Fresenius Kabi will be fully responsible for the marketing of Vifor’s intravenous iron portfolio in China.

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

CSL reports its third consecutive earnings miss, with 1H25 revenue up 5% but NPATA falling short of consensus expectations ...

Research, development, manufacture, marketing and distribution of biopharmaceutical products and vaccines.